Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:30pm GMT / 7:30am EST in London.

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President & Chief Executive Officer Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Dennis Ding - Jefferies Roanna Ruiz - Leerink Partners Laura Chico - Wedbush Joseph Thome - TD Cowen Ryan Deschner - Raymond James Matt Kaplan - Ladenburg Thalmann Chris Raymond - Piper Sandler & Co. Operator Good afternoon, ladies and gentlemen and welcome to the Ardelyx Third Quarter 2024 Earnings Call. Our host for today's call is Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx.

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics

Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.03 per share a year ago.

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that results from the IBS in America 2024 supplemental survey, in partnership with Health Union, were presented at the American College of Gastroenterology's (ACG) Annual Scientific Meeting & Postgraduate Course, currently taking place in Philadelphia.

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of long-term stockholders following a class action complaint that was filed against Ardelyx on August 16, 2024, with a Class Period from October 31, 2023 to July 1, 2024. Our investigation concerns whether the board of directors of Ardelyx have breached their fiduciary duties to the company.

ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx's director, patient advocacy, Johannah Ruddy, M.Ed. and practicing gastroenterologist, Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroenterology experts to discuss the impact of IBS-C and provide education and hope for those affected.

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

After losing some value lately, a hammer chart pattern has been formed for Ardelyx (ARDX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher

WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 31, 2024, at 4:30 p.m.

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=108598&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=108516&wire=1 or contact Joseph E. Levi, Esq.

Ardelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-12119, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Ardelyx securities between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting XPHOZAH® (tenapanor) will be presented at the American Society of Nephrology's (ASN) Kidney Week, to be held October 24-27, 2024, in San Diego.

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=108458&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class Action - ARDX

NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ardelyx securities between October 31, 2023, and July 1, 2024, inclusive (the "Class Period").

FINAL ARDX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ardelyx, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ardelyx investors who were adversely affected by alleged securities fraud between October 31, 2023 and July 1, 2024.

ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=108399&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) of a class action securities lawsuit.

Ardelyx, Inc. Class Action: Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=108347&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class Action - ARDX

LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a category motion lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ:ARDX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Ardelyx, Inc.

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / If you suffered a loss on your Ardelyx, Inc. (NASDAQ:ARDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ardelyx-lawsuit-submission-form?prid=108320&wire=1 or contact Joseph E. Levi, Esq.

Investors Who Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class Action - ARDX

LOS ANGELES , Oct. 14, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2023 and July 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 15, 2024.

News for Ardelyx Stock (ARDX)